Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Hematological Oncology|November 26, 2022
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studyKazutaka Sunami, Shin-Ichi Fuchida, Kenshi Suzuki, et al.
Leukemia & Lymphoma|August 28, 2020
Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphomaYoshiaki Chinen, Kazuna Tanba, Ryo Takagi, et al.
Blood|July 5, 2005
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemiaTatsuya Suzuki, Hitoshi Kiyoi, Kazutaka Ozeki, et al.
European Journal of Haematology|July 28, 2007
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myelomaHirokazu Murakami, Hiroshi Handa, Masahiro Abe, et al.
Cancer Science|September 25, 2020
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy studyKazutaka Sunami, Kenshi Suzuki, Masaki Ri, et al.
International Journal of Hematology|November 16, 2004
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical studyYasuo Morishima, Michinori Ogura, Miki Nishimura, et al.
International Journal of Hematology|October 7, 2010
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and OsakaTsutomu Kobayashi, Junya Kuroda, Kazuho Shimura, et al.
Annals of Hematology|August 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patientsYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, et al.
Leukemia & Lymphoma|February 11, 2022
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myelomaAyako Muramatsu, Tsutomu Kobayashi, Yuka Kawaji-Kanayama, et al.
Hematology (Amsterdam, Netherlands)|April 29, 2025
Insights into very elderly multiple myeloma treatment from Kansai Myeloma ForumYusuke Okayama, Teruhito Takakuwa, Yuji Shimura, et al.
Pageof 13